Summary from GEO: "Current research on CDK4/6 inhibitors (CDK4/6i) in the pre-clinical and clinical spaces are largely concerned with gaining a deeper understanding of how these drugs delay tumor growth, and how to prevent cancer cell resistance. By coordinating a first-in-kind phase II clinical trial of the CDK4/6i abemaciclib for patients with progressive dedifferentiated liposarcoma (DDLS) with...

Summary from GEO: "Orthoganally complementing our RNA-seq (GSE241031) efforts to define transcriptional changes over time in LS8817(TetOnFMDM2) cells as they progressed from quiesence to senescence, we chose to look at gene expression in unperturbed parental and 10 day palbociclib treated LS8817 parental cells" Overall design from GEO: "Asynchronously growing LS8817 cells were treated with 1...